YM BioSciences and AEterna Zentaris -- Starting Strong in 2012
February 07 2012 - 8:20AM
Marketwired
Biotech stocks are on fire in 2012. The iShares NASDAQ
Biotechnology index is up more than 15 percent year-to-date as
impressive earnings results have boosted investor optimism in the
industry. According to BB Biotech, "neither the government debt
crisis nor recessionary pressures nor all the turmoil on the
currency front" have been able to slow the biotech sector. The
Paragon Report examines investing opportunities in the
Biotechnology Industry and provides equity research on YM
BioSciences, Inc. (NYSE Amex: YMI) (TSX: YM) and AEterna Zentaris,
Inc. (NASDAQ: AEZS) (TSX: AEZ). Access to the full company reports
can be found at:
www.paragonreport.com/YMI www.paragonreport.com/AEZS
BB Biotech says that the expected news flow from biotech
pipelines in 2012 "also bodes well" for the industry in the current
year. In 2011, regulators approved 13 new biotech products and
major R&D milestones were reached all while the industry's
revenues and profits exceeded market expectations, BB observes.
Global Industry Analysts, Inc. (GIA) says that improving
economic conditions have led to an increase in funding for the
biotechnology industry. GIA predicts that the global market for
biotechnology will surpass $320 billion by 2015 thanks to increased
availability of funding for R&D.
The Paragon Report provides investors with an excellent first
step in their due diligence by providing daily trading ideas, and
consolidating the public information available on them. For more
investment research on the biotechnology industry register with us
free at www.paragonreport.com and get exclusive access to our
numerous stock reports and industry newsletters.
Aeterna Zentaris Inc. operates as a late-stage drug development
company specialized in oncology and endocrine therapy. Last week
the company reported 'positive' updated results for the Phase 1
portion of its ongoing Phase 1/2 study in castration- and
taxane-resistant prostate cancer (CRPC) with AEZS-108 (zoptarelin
doxorubicin), the co's targeted cytotoxic luteinizing
hormone-releasing hormone analog.
YM BioSciences Inc., a drug development company, develops,
markets, and commercializes hematology and cancer-related products.
Its products include CYT387, a small molecule pyrimidine kinase
inhibitor that is in Phase I/II clinical trial for the treatment of
patients with myelofibrosis, a chronic debilitating disease; and
CYT 997, a small molecule microtubule polymerisation inhibitor and
vascular disrupting agent, which is Phase Ib/II clinical study for
the treatment of solid tumors.
The Paragon Report has not been compensated by any of the
above-mentioned publicly traded companies. Paragon Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.paragonreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024